[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (4,943)

Search Parameters:
Keywords = EpiDerm®

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
17 pages, 716 KiB  
Article
Fabrication and Evaluation of Polyhydroxyalkanoate-Based Nanoparticles for Curcumin Delivery in Biomedical Applications
by Fawzia Sha’at, Dana Miu, Mihaela Carmen Eremia, Georgeta Neagu, Adrian Albulescu, Radu Albulescu, Mihaela Deaconu, Mariana Gratiela Vladu and Ramona-Daniela Pavaloiu
Molecules 2025, 30(6), 1216; https://doi.org/10.3390/molecules30061216 (registering DOI) - 8 Mar 2025
Abstract
This study investigates the fabrication and characterization of polymeric nanoparticles based on polyhydroxyalkanoates (PHAs) loaded with curcumin for biomedical applications. PHAs, biodegradable and biocompatible polymers, were synthesized via bacterial fermentation and used to encapsulate curcumin using the nanoprecipitation method. The resulting nanoparticles were [...] Read more.
This study investigates the fabrication and characterization of polymeric nanoparticles based on polyhydroxyalkanoates (PHAs) loaded with curcumin for biomedical applications. PHAs, biodegradable and biocompatible polymers, were synthesized via bacterial fermentation and used to encapsulate curcumin using the nanoprecipitation method. The resulting nanoparticles were characterized for their particle size, polydispersity index, and encapsulation efficiency, achieving high entrapment rates (above 80%) and nanometric size distribution. Stability assessments demonstrated prolonged structural integrity under storage conditions. In vitro release studies conducted in phosphate-buffered saline at pH 5 and 7.4 revealed sustained drug release profiles. Biocompatibility and cytotoxicity assays using human astrocytes and fibroblasts confirmed the nanoparticles’ safety, while antiproliferative tests on glioblastoma and colon cancer cell lines indicated potential therapeutic efficacy. Additionally, skin irritation and corrosion tests using the EpiDerm™ model classified the formulations as non-irritant and non-corrosive. These findings suggest that PHA-based nanoparticles offer a promising nanocarrier system for curcumin delivery, with potential applications in cancer treatment and regenerative medicine. Future research should focus on optimizing the formulation and evaluating in vivo therapeutic effects. Full article
(This article belongs to the Special Issue Molecular Approaches to Drug Discovery and Development)
Show Figures

Figure 1

Figure 1
<p>The release profiles of curcumin from nanoparticles based on polyhydroxyalkanoates in PBS 0.1 M pH 5 (<b>A</b>) compared to PBS 0.1 M pH 7.4 (<b>B</b>). The release followed the trend PHH &lt; PHO &lt; PHN in both media, indicating a composition-dependent effect on drug release.</p>
Full article ">Figure 2
<p>Antiproliferative effects of curcumin and PHA-based nanoparticles loaded with curcumin on U87 cells (<b>A</b>,<b>B</b>) and Caco-2 cells (<b>C</b>,<b>D</b>) after 24 and 48 h. Control is referring to untreated cells. Data are presented as the mean ± standard deviation. The results are considered statistically significant at <span class="html-italic">p</span> &lt; 0.05.</p>
Full article ">
22 pages, 5118 KiB  
Article
Panduratin A from Boesenbergia rotunda Effectively Inhibits EGFR/STAT3/Akt Signaling Pathways, Inducing Apoptosis in NSCLC Cells with Wild-Type and T790M Mutations in EGFR
by Wanna Eiamart, Piyanuch Wonganan, Sarin Tadtong and Weerasak Samee
Int. J. Mol. Sci. 2025, 26(5), 2350; https://doi.org/10.3390/ijms26052350 - 6 Mar 2025
Viewed by 124
Abstract
Non-small cell lung cancer (NSCLC) is a challenging disease, with the epidermal growth factor receptor (EGFR) being a key target for new, effective treatments crucial for the signaling pathways regulating cancer cell survival. Targeting EGFR-mediated signaling offers promising strategies to improve NSCLC therapies, [...] Read more.
Non-small cell lung cancer (NSCLC) is a challenging disease, with the epidermal growth factor receptor (EGFR) being a key target for new, effective treatments crucial for the signaling pathways regulating cancer cell survival. Targeting EGFR-mediated signaling offers promising strategies to improve NSCLC therapies, particularly in overcoming resistance in EGFR-mutant lung cancer. In this study, we investigated the anticancer effects of panduratin A, a naturally occurring flavonoid from Boesenbergia rotunda, on human NSCLC cell lines expressing both wild-type EGFR (A549) and mutant EGFR (H1975) using in vitro experiments and molecular docking approaches. Cytotoxicity screening revealed that panduratin A exhibits potent effects on both A549 (IC50 of 6.03 ± 0.21 µg/mL) and H1975 (IC50 of 5.58 ± 0.15 µg/mL) cell lines while demonstrating low toxicity to normal MRC5 lung cells (12.96 ± 0.36 µg/mL). Furthermore, western blotting and flow cytometric analyses indicated that panduratin A induces apoptosis by inhibiting p-EGFR and its downstream effectors, p-STAT3 and p-Akt, in lung cancer cells. Additionally, the docking study showed lower binding energy between panduratin A and the target proteins, comparable to that of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs). The ADMET prediction also highlighted panduratin A’s exceptional drug-like properties. This study concludes that panduratin A shows significant promise as an anti-lung cancer candidate for NSCLC, offering an economical and effective strategy. Full article
(This article belongs to the Special Issue Anticancer Activity of Natural Products and Related Compounds)
Show Figures

Figure 1

Figure 1
<p>Chemical structures of (<b>A</b>) pinostrobin and (<b>B</b>) panduratin A.</p>
Full article ">Figure 2
<p>Cell viability of (<b>A</b>,<b>C</b>,<b>D</b>) A549, H1975, and (<b>B</b>) MRC5 cell lines after treatment with various concentrations of panduratin A (PA), gefitinib (GEF), and osimertinib (OSI) for 24 h. Data are expressed as the mean ± SEM of three independent experiments. ** <span class="html-italic">p</span> ≤ 0.01, *** <span class="html-italic">p</span> ≤ 0.001, and **** <span class="html-italic">p</span> ≤ 0.0001 vs. control.</p>
Full article ">Figure 3
<p>Morphological changes in A549 and H1975 cell lines after 24 h treatment with various concentrations of panduratin A. Microscope images were taken at 4X.</p>
Full article ">Figure 4
<p>Flow cytometric analysis of Annexin V/PI-stained cells after panduratin A (PA) treatment for 24 h on A549 (<b>A</b>,<b>B</b>) and H1975 (<b>C</b>,<b>D</b>) cells. Representative figures showing populations of viable (Q3), early apoptotic (Q4), late apoptotic (Q2), and necrotic (Q1) cells. The red dot plot displaying the cell population by fluorescence intensity. Data are expressed as the mean ± SEM of three independent experiments. **** <span class="html-italic">p</span> ≤ 0.0001 vs. control.</p>
Full article ">Figure 5
<p>Panduratin A (PA) inhibits the phosphorylation of EGFR (<b>A</b>,<b>B</b>), STAT3 (<b>C</b>,<b>D</b>), and Akt (<b>E</b>,<b>F</b>) in A549 and H1975 cells at 24 h. Data are expressed as the mean ± SEM of three independent experiments. * <span class="html-italic">p</span> ≤ 0.05, ** <span class="html-italic">p</span> ≤ 0.01, *** <span class="html-italic">p</span> ≤ 0.001, and **** <span class="html-italic">p</span> ≤ 0.0001 vs. control.</p>
Full article ">Figure 5 Cont.
<p>Panduratin A (PA) inhibits the phosphorylation of EGFR (<b>A</b>,<b>B</b>), STAT3 (<b>C</b>,<b>D</b>), and Akt (<b>E</b>,<b>F</b>) in A549 and H1975 cells at 24 h. Data are expressed as the mean ± SEM of three independent experiments. * <span class="html-italic">p</span> ≤ 0.05, ** <span class="html-italic">p</span> ≤ 0.01, *** <span class="html-italic">p</span> ≤ 0.001, and **** <span class="html-italic">p</span> ≤ 0.0001 vs. control.</p>
Full article ">Figure 6
<p>Mechanisms of panduratin A (PA) against A549 and H1975 NSCLC cell lines, in which panduratin A promotes cell apoptosis through the inhibition of p-EGFR, p-Akt, and p-STAT3 signaling pathways. The black arrow indicates activation, the red arrow indicates inhibition, and the green down arrow indicates down-regulation of the protein.</p>
Full article ">Figure 7
<p>Binding interactions of panduratin A with (<b>A</b>) EGFR<sup>WT</sup> (7UKV), (<b>B</b>) EGFR<sup>T790M</sup> (5Y9T), (<b>C</b>) STAT3 (1BG1), and (<b>D</b>) Akt (4GV1).</p>
Full article ">Figure 8
<p>Pink zoned oral bioavailability radars for (<b>A</b>) panduratin A (PA), (<b>B</b>) pinostrobin (PN), (<b>C</b>) osimertinib (OSI), and (<b>D</b>) gefitinib (GEF).</p>
Full article ">Figure 8 Cont.
<p>Pink zoned oral bioavailability radars for (<b>A</b>) panduratin A (PA), (<b>B</b>) pinostrobin (PN), (<b>C</b>) osimertinib (OSI), and (<b>D</b>) gefitinib (GEF).</p>
Full article ">Figure 9
<p>Boiled Egg plot showing water partition coefficient (WlogP) vs. topological polar surface area (TPSA) of panduratin A (PA) and pinostrobin (PN) compared with reference drugs osimertinib (OSI) and gefitinib (GEF).</p>
Full article ">
12 pages, 1439 KiB  
Article
GDF15, EGF, and Neopterin in Assessing Progression of Pediatric Chronic Kidney Disease Using Artificial Intelligence Tools—A Pilot Study
by Kinga Musiał, Jakub Stojanowski, Agnieszka Bargenda-Lange and Tomasz Gołębiowski
Int. J. Mol. Sci. 2025, 26(5), 2344; https://doi.org/10.3390/ijms26052344 - 6 Mar 2025
Viewed by 65
Abstract
Cell-mediated immunity and chronic inflammation are hallmarks of chronic kidney disease (CKD). Growth differentiation factor 15 (GDF15) is a marker of inflammation and an integrative signal in stress conditions. Epidermal growth factor (EGF) is a tubule-specific protein that modulates the regeneration of injured [...] Read more.
Cell-mediated immunity and chronic inflammation are hallmarks of chronic kidney disease (CKD). Growth differentiation factor 15 (GDF15) is a marker of inflammation and an integrative signal in stress conditions. Epidermal growth factor (EGF) is a tubule-specific protein that modulates the regeneration of injured renal tubules. Neopterin is a product of activated monocytes and macrophages and serves as a marker of cell-mediated immunity. Our aim was to assess the role of the above-mentioned parameters in the progression of CKD in children using artificial intelligence tools. The study group consisted of 151 children with CKD stages 1–5. EGF, GDF15, and neopterin serum concentrations were assessed by ELISA. The patients’ anthropometric data, biochemical parameters, EGF, GDF15, and neopterin serum values were implemented into the artificial neural network (ANN). The most precise model contained EGF, GDF15, and neopterin as input parameters and classified patients into either CKD 1–3 or CKD 4–5 groups with an excellent accuracy of 96.77%. The presented AI model, with serum concentrations of EGF, GDF15, and neopterin as input parameters, may serve as a useful predictor of CKD progression. It suggests the essential role of inflammatory processes in the renal function decline in the course of CKD in children. Full article
(This article belongs to the Special Issue Machine Learning in Disease Diagnosis and Treatment)
Show Figures

Figure 1

Figure 1
<p>Parameter serum concentrations in examined groups: (<b>a</b>) GDF15; (<b>b</b>) EGF; (<b>c</b>) neopterin; CKD I–V—chronic kidney disease stage I–V; GDF15—growth differentiation factor 15; EGF—epidermal growth factor.</p>
Full article ">Figure 2
<p>The artificial neural network model with EGF, GDF15, and neopterin as input data. The colors of the connections between the neurons represented by the round nodes correspond to the weights of the connections—positive weight values are more intensely red, and negative weights are more intensely blue. The input layer contains 3 input parameters, then there are 2 hidden layers, in which each of the neurons of a given layer has connections with all of the next layer. The output layer is one neuron, which takes the value 0 or 1 corresponding to CKD 1–3 or CKD 4–5.</p>
Full article ">Figure 3
<p>ROC for multilayer perceptron model. AUC—area under the curve, LOOCV—leave-one-out cross-validation.</p>
Full article ">
20 pages, 20795 KiB  
Article
Effects of Pharmacological Dose of Vitamin C on MDA-MB-231 Cells
by Lunawati Lo Bennett
Biomedicines 2025, 13(3), 640; https://doi.org/10.3390/biomedicines13030640 - 5 Mar 2025
Viewed by 139
Abstract
Background/Objectives: In 2022, approximately 2.3 million women were diagnosed with breast cancer worldwide, resulting in 670,000 deaths, which accounted for 6.9% of all cancer-related deaths. In the United States, 1 in 8 women will be diagnosed with breast cancer during their lifetime. It [...] Read more.
Background/Objectives: In 2022, approximately 2.3 million women were diagnosed with breast cancer worldwide, resulting in 670,000 deaths, which accounted for 6.9% of all cancer-related deaths. In the United States, 1 in 8 women will be diagnosed with breast cancer during their lifetime. It was estimated that 2024 would identify about 310,720 women and 2800 men diagnosed with invasive breast cancer. The future global burden of breast cancer is projected to rise to over 3 million new cases and 1 million deaths by 2040. Approximately 20% of breast cancer diagnoses are triple-negative breast cancer (TNBC), a type of cancer that lacks receptors for estrogen (ER-negative), progesterone (PR-negative), and human epidermal growth factor receptor 2 (HER2/neu-negative). Consequently, TNBC does not respond to hormonal or targeted therapies, making it challenging to treat due to its rapid growth, metastasis, and high recurrence rate within the first three years of therapy. Alternative chemotherapies are needed to address this problem. A pharmacological dose of vitamin C (high-dose VC) has been identified as a potential treatment for some cancer cells. The present study aimed to evaluate whether VC has a therapeutic effect on TNBC, using MDA-MB-231 cells as the model. Additionally, VC’s effects were trialed on other cancer cells such as MCF7 and on non-cancerous kidney HEK 293 and lung CCL205 cells. Methods: The MTT assay, Hoechst 33342 staining, nuclear-ID red/green staining, Rhodamine 123 staining, and Western blot analysis were employed to test the hypothesis that a pharmacological dose of VC can kill TNBC cells. Results: The upregulation of Apaf-1 and caspases -7, -8, and -9, the inhibition of matrix metalloproteinases (MMP-2 and MMP-9), a reduction in cell cycle protein expression, and the enhancement of tumor suppressor proteins such as p53 and p21 indicate that a pharmacological dose of VC has promising anti-cancer properties in the treatment of breast cancers. Conclusions: Pharmacological dose of VC exerts significant anti-cancer effects in MDA-MB-231 cells by promoting apoptosis, inhibiting metastasis, disrupting cell cycle progression, and enhancing tumor suppressor activity. Full article
Show Figures

Figure 1

Figure 1
<p>(<b>a</b>) MTT result of cell viability MDA-MB-231 cells treated with VC from 0 to 125 mM. (<b>b</b>) shows MCF7 cells treated with VC from 0 to 125 mM. (<b>c</b>) shows that rat spleen had higher % cell viability with treatment of VC at 2.5 mM and 8 mM showing non-cytotoxic effect of VC on normal cells.</p>
Full article ">Figure 2
<p>Inverted microscopic images of MDA-MB-231 and MCF7 cancer cells after 24 h of treatment with VC at concentrations of 8 mM and 16 mM for MDA-MB-231, and with VC at concentrations of 4 mM and 7 mM for MCF7. Higher concentrations of VC led to increased cell death in both MDA-MB-231 and MCF7 compared to their respective controls (<b>a,b</b>). In contrast, VC at 5 mM and 15 mM promoted cell growth in non-cancerous HEK-293 kidney cells (<b>c</b>). The scale bar represents 40×.</p>
Full article ">Figure 3
<p>Image (<b>a</b>) displays inverted microscope images of cell migration following the 24 h treatment of MDA-MB-231 cells with VC 8 mM or 16 mM VC, while MCF7 cells received 4 mM and 7 mM of VC. In the control groups, a narrow scratch area indicated maximal cancer cell migration, whereas VC-treated cells exhibited a wider scratch area, reflecting reduced migration (<b>a</b>,<b>c</b>). Conversely, VC at 5 mM and 15 mM enhanced cell growth in non-cancerous HEK 293 kidney cells, as evidenced by a decreased scratch width (<b>e</b>). Figures (<b>b</b>,<b>d</b>,<b>f</b>) presents the corresponding histograms, with ** <span class="html-italic">p</span> &lt; 0.01 and *** <span class="html-italic">p</span> &lt; 0.001 (post hoc Newman–Keuls test) compared to the 0 h measurements of the corresponding control cells.</p>
Full article ">Figure 3 Cont.
<p>Image (<b>a</b>) displays inverted microscope images of cell migration following the 24 h treatment of MDA-MB-231 cells with VC 8 mM or 16 mM VC, while MCF7 cells received 4 mM and 7 mM of VC. In the control groups, a narrow scratch area indicated maximal cancer cell migration, whereas VC-treated cells exhibited a wider scratch area, reflecting reduced migration (<b>a</b>,<b>c</b>). Conversely, VC at 5 mM and 15 mM enhanced cell growth in non-cancerous HEK 293 kidney cells, as evidenced by a decreased scratch width (<b>e</b>). Figures (<b>b</b>,<b>d</b>,<b>f</b>) presents the corresponding histograms, with ** <span class="html-italic">p</span> &lt; 0.01 and *** <span class="html-italic">p</span> &lt; 0.001 (post hoc Newman–Keuls test) compared to the 0 h measurements of the corresponding control cells.</p>
Full article ">Figure 4
<p>(<b>a</b>) displays fluorescence microscopy images of MDA-MB-231 control cells alongside cells treated with 8 mM and 16 mM VC for 24 h, followed by Hoechst 33342 staining. (<b>b</b>) illustrates a histogram comparing the percentage of apoptotic and live cells relative to the control. (<b>c</b>) presents Western blot analysis showing the expression levels of Bax, Bcl-2, and cytochrome C, while (<b>d</b>) provides a histogram comparing these expression levels to the control group. In MCF7 cells, fluorescence analysis revealed significant changes in the live-to-apoptotic cell ratio (<b>e</b>,<b>f</b>). In contrast, VC treatment at 5 mM and 15 mM in non-cancerous HEK 293 kidney cells or CCL 205 lung cells did not significantly affect this ratio, indicating no cytotoxic effect on non-cancerous cells (<b>g</b>–<b>j</b>). The scale bar represents 100 µm. Statistical significance was determined using the post hoc Newman–Keuls test ** <span class="html-italic">p</span> &lt; 0.01, and *** <span class="html-italic">p</span> &lt; 0.001) compared to the respective controls.</p>
Full article ">Figure 4 Cont.
<p>(<b>a</b>) displays fluorescence microscopy images of MDA-MB-231 control cells alongside cells treated with 8 mM and 16 mM VC for 24 h, followed by Hoechst 33342 staining. (<b>b</b>) illustrates a histogram comparing the percentage of apoptotic and live cells relative to the control. (<b>c</b>) presents Western blot analysis showing the expression levels of Bax, Bcl-2, and cytochrome C, while (<b>d</b>) provides a histogram comparing these expression levels to the control group. In MCF7 cells, fluorescence analysis revealed significant changes in the live-to-apoptotic cell ratio (<b>e</b>,<b>f</b>). In contrast, VC treatment at 5 mM and 15 mM in non-cancerous HEK 293 kidney cells or CCL 205 lung cells did not significantly affect this ratio, indicating no cytotoxic effect on non-cancerous cells (<b>g</b>–<b>j</b>). The scale bar represents 100 µm. Statistical significance was determined using the post hoc Newman–Keuls test ** <span class="html-italic">p</span> &lt; 0.01, and *** <span class="html-italic">p</span> &lt; 0.001) compared to the respective controls.</p>
Full article ">Figure 5
<p>(<b>a</b>) Fluorescence microscopic images of MDA-MB-231cells after 24 h treatment with VC 8 mM or VC 16 mM and staining with Rhodamine 123. (<b>b</b>) Histogram represents percentage of cells changing in mitochondrial membrane potential, with higher VC showing pronounced decrease in membrane potential and darker cells compared to control. (<b>c</b>) Shows Western blot analysis of different signaling activity proteins involved in caspase cascade and Apaf-1. (<b>d</b>) Histogram represents upregulation of Apaf-1 and cas-3 and -9 in cells treated with VC 8 mM or 16 mM in MD-MBA-231 cells. Fluorescence analysis of MCF7 also showed pronounced decrease in cells treated with VC 4 mM and 7 mM, with the histogram representing the change in fluorescence (<b>e</b>,<b>f</b>). In contrast, VC treatment at 5 mM and 15 mM in non-cancerous HEK 293 and CCL 205 cells showed significant increase in membrane potential assuring favorable effect of VC in non-cancerous cells (<b>g</b>,<b>i</b>). The histograms show the effect of VC on HEK 293 and CCL 205 (<b>h</b>,<b>j</b>). Scale bar represents 100 µm. Significant change in mitochondrial membrane potential for treatment vs. control group, ** <span class="html-italic">p</span> &lt; 0.01 and *** <span class="html-italic">p</span> &lt; 0.001, post hoc Newman–Keuls test.</p>
Full article ">Figure 5 Cont.
<p>(<b>a</b>) Fluorescence microscopic images of MDA-MB-231cells after 24 h treatment with VC 8 mM or VC 16 mM and staining with Rhodamine 123. (<b>b</b>) Histogram represents percentage of cells changing in mitochondrial membrane potential, with higher VC showing pronounced decrease in membrane potential and darker cells compared to control. (<b>c</b>) Shows Western blot analysis of different signaling activity proteins involved in caspase cascade and Apaf-1. (<b>d</b>) Histogram represents upregulation of Apaf-1 and cas-3 and -9 in cells treated with VC 8 mM or 16 mM in MD-MBA-231 cells. Fluorescence analysis of MCF7 also showed pronounced decrease in cells treated with VC 4 mM and 7 mM, with the histogram representing the change in fluorescence (<b>e</b>,<b>f</b>). In contrast, VC treatment at 5 mM and 15 mM in non-cancerous HEK 293 and CCL 205 cells showed significant increase in membrane potential assuring favorable effect of VC in non-cancerous cells (<b>g</b>,<b>i</b>). The histograms show the effect of VC on HEK 293 and CCL 205 (<b>h</b>,<b>j</b>). Scale bar represents 100 µm. Significant change in mitochondrial membrane potential for treatment vs. control group, ** <span class="html-italic">p</span> &lt; 0.01 and *** <span class="html-italic">p</span> &lt; 0.001, post hoc Newman–Keuls test.</p>
Full article ">Figure 6
<p>(<b>a</b>) shows the results of intracellular ROS generation in MDA-MB-231 cells using the H2DCFDA staining method. Control cells displayed minimal ROS formation, as indicated by darker green fluorescence. In contrast, cells treated with VC at 8 mM and 16 mM exhibited increased ROS levels, as characterized by progressively brighter green fluorescence. The intensity of ROS generation was directly proportional to the concentration of VC, with 16 mM showing the highest level of ROS. (<b>b</b>) presents a histogram comparing ROS levels in treated cells versus control. To further evaluate the effect of VC on different cell lines, ROS generation was also assessed in MCF7 cells and non-cancerous HEK 293 kidney and CCL 205 lung cells. MCF cells demonstrated a similar increase in ROS as MDA-MB-231 cells (<b>c</b>) with histogram presented (<b>d</b>). Non-cancerous HEK 293 and CCL 205 cells exhibited significantly lower levels of ROS in response to VC treatment, suggesting a minimal or non-cytotoxic effect of VC on non-cancerous cells (<b>e</b>–<b>h</b>). Scale bar indicated 100 µm. A significant change in intracellular ROS generation versus control, *** <span class="html-italic">p</span> &lt; 0.001, post hoc Newman–Keuls test.</p>
Full article ">Figure 6 Cont.
<p>(<b>a</b>) shows the results of intracellular ROS generation in MDA-MB-231 cells using the H2DCFDA staining method. Control cells displayed minimal ROS formation, as indicated by darker green fluorescence. In contrast, cells treated with VC at 8 mM and 16 mM exhibited increased ROS levels, as characterized by progressively brighter green fluorescence. The intensity of ROS generation was directly proportional to the concentration of VC, with 16 mM showing the highest level of ROS. (<b>b</b>) presents a histogram comparing ROS levels in treated cells versus control. To further evaluate the effect of VC on different cell lines, ROS generation was also assessed in MCF7 cells and non-cancerous HEK 293 kidney and CCL 205 lung cells. MCF cells demonstrated a similar increase in ROS as MDA-MB-231 cells (<b>c</b>) with histogram presented (<b>d</b>). Non-cancerous HEK 293 and CCL 205 cells exhibited significantly lower levels of ROS in response to VC treatment, suggesting a minimal or non-cytotoxic effect of VC on non-cancerous cells (<b>e</b>–<b>h</b>). Scale bar indicated 100 µm. A significant change in intracellular ROS generation versus control, *** <span class="html-italic">p</span> &lt; 0.001, post hoc Newman–Keuls test.</p>
Full article ">Figure 7
<p>(<b>a</b>) Fluorescence microscopic images from alive and death nucleic acid staining using nuclear-ID red/green cell viability method. (<b>b</b>) The histogram represents the percentage of alive or death from cells treated with VC 8 mM or VC 18 16 mM vs. control of MDA-MB-231. (<b>c</b>–<b>h</b>) depict the effects of varying VC concentrations on cell viability in MCF7 cancer cells, non-cancerous HEK 293 kidney cells, and CCL 205 lung cells. MCF7 cells exhibited an increase in cell death at higher VC concentrations: 7 mM vs 4 mM (<b>c</b>,<b>d</b>). As the VC dose increased, a higher proportion of cells were stained red, reflecting the cytotoxic effects of VC. Control HEK 293 and CCL 205 cells versus cells treated with 5 mM or 15 mM VC displayed a similar proportion of live and dead cells, indicating that VC had no significant cytotoxic effect on these non-cancerous cell lines. The green fluorescence in both HEK 293 and CCL 205 cells was predominant, signifying high cell viability in both control and VC-treated groups (<b>e</b>–<b>h</b>). These findings highlight VC’s selective cytotoxicity, with higher concentrations inducing cell death in cancerous MDA-MB-231 and MCF7 cells, while non-cancerous HEK 293 and CCL 205 cells remained largely unaffected. Scale bar indicates 100 µm. Significant change in cells death due to VC treatment versus control, ** <span class="html-italic">p</span> &lt; 0.01 and *** <span class="html-italic">p</span> &lt; 0.001, post hoc Newman–Keuls test.</p>
Full article ">Figure 7 Cont.
<p>(<b>a</b>) Fluorescence microscopic images from alive and death nucleic acid staining using nuclear-ID red/green cell viability method. (<b>b</b>) The histogram represents the percentage of alive or death from cells treated with VC 8 mM or VC 18 16 mM vs. control of MDA-MB-231. (<b>c</b>–<b>h</b>) depict the effects of varying VC concentrations on cell viability in MCF7 cancer cells, non-cancerous HEK 293 kidney cells, and CCL 205 lung cells. MCF7 cells exhibited an increase in cell death at higher VC concentrations: 7 mM vs 4 mM (<b>c</b>,<b>d</b>). As the VC dose increased, a higher proportion of cells were stained red, reflecting the cytotoxic effects of VC. Control HEK 293 and CCL 205 cells versus cells treated with 5 mM or 15 mM VC displayed a similar proportion of live and dead cells, indicating that VC had no significant cytotoxic effect on these non-cancerous cell lines. The green fluorescence in both HEK 293 and CCL 205 cells was predominant, signifying high cell viability in both control and VC-treated groups (<b>e</b>–<b>h</b>). These findings highlight VC’s selective cytotoxicity, with higher concentrations inducing cell death in cancerous MDA-MB-231 and MCF7 cells, while non-cancerous HEK 293 and CCL 205 cells remained largely unaffected. Scale bar indicates 100 µm. Significant change in cells death due to VC treatment versus control, ** <span class="html-italic">p</span> &lt; 0.01 and *** <span class="html-italic">p</span> &lt; 0.001, post hoc Newman–Keuls test.</p>
Full article ">Figure 8
<p>(<b>a</b>) Western blot analysis of proteins involved in cell cycle regulation. The expression of CDK2, cyclin D1, and cyclin B1 significantly decreased in cells treated with VC. (<b>b</b>) shows histogram downregulation of these proteins compared to its control, ** <span class="html-italic">p</span> &lt; 0.01 and *** <span class="html-italic">p</span>&lt; 0.001, post hoc Newman–Keuls test.</p>
Full article ">Figure 9
<p>(<b>a</b>) Western blot analysis of MMP2 and MMP9 proteins. (<b>b</b>) Histogram represents downregulation of these proteins vs. control group. Significant decrease in protein expressions *** <span class="html-italic">p</span>&lt; 0.001, post hoc Newman–Keuls test.</p>
Full article ">Figure 10
<p>(<b>a</b>) Western blot analysis of p21, p53, pTEN, and MDM2 proteins. (<b>b</b>) Histogram represents the upregulation of p21, p53 and pTEN proteins and the downregulation of MDM2 as compared to the control. Significant change in protein expressions vs. control, ** <span class="html-italic">p</span> &lt; 0.01 and *** <span class="html-italic">p</span>&lt; 0.001, post hoc Newman–Keuls test.</p>
Full article ">Figure 11
<p>(<b>a</b>) Western blot analysis of p13k, Akt, and mTOR proteins. (<b>b</b>) Histogram represents the downregulation of p13k, Akt, and mTOR proteins from cells treated with VC as compared to the control. Significant change in protein expressions *** <span class="html-italic">p</span>&lt; 0.001, post hoc Newman–Keuls test.</p>
Full article ">Figure 12
<p>The proposed mechanism of action of a high dose of VC on MDA-MB 231 cells.</p>
Full article ">
12 pages, 748 KiB  
Article
Real-World Data on Osimertinib-Associated Cardiac Toxicity
by Abed Agbarya, Ari Raphael, Hadas Gantz Sorotsky, Yakir Rottenberg, Viktor Šebek, Dejan Radonjic, Alexander Yakobson, Johnathan Arnon and Walid Shalata
J. Clin. Med. 2025, 14(5), 1754; https://doi.org/10.3390/jcm14051754 - 5 Mar 2025
Viewed by 151
Abstract
Background: Lung cancer is the leading cause of cancer-related deaths globally, with epidermal growth factor receptor (EGFR) mutations present in approximately 17–39% of non-small cell lung cancer (NSCLC) cases. Osimertinib, a third-generation oral EGFR tyrosine kinase inhibitor (EGFR-TKI), has become a cornerstone [...] Read more.
Background: Lung cancer is the leading cause of cancer-related deaths globally, with epidermal growth factor receptor (EGFR) mutations present in approximately 17–39% of non-small cell lung cancer (NSCLC) cases. Osimertinib, a third-generation oral EGFR tyrosine kinase inhibitor (EGFR-TKI), has become a cornerstone in the treatment of EGFR-mutated NSCLC. However, the full scope of its potentially life-threatening adverse effects, particularly cardiomyopathy, remains underexplored. Methods: This retrospective study was conducted using data from a multi-center registry of NSCLC patients with EGFR mutations treated with first-line osimertinib therapy between December 2018 and April 2024. Osimertinib-related cardiotoxicity was defined as a composite of reduced ejection fraction (EF) and cardiac death. Results: The study cohort consisted of 17 patients, and most of the patients had a history of smoking. Cardiac toxicity onset varied from 1 to 28 months following osimertinib initiation, with 70.59% of the patients experiencing symptoms within the first 6 months of treatment. Fourteen patients showed some degree of symptom improvement and EF recovery, although most did not return to baseline EF levels. Comorbidities, including heart failure, hypertension, and dyslipidemia, were prevalent across the cohort. Conclusions: While osimertinib remains an effective treatment for EGFR-mutated NSCLC, its associated cardiac toxicity, particularly in patients with pre-existing conditions, presents a significant challenge. Close monitoring, early intervention, and individualized management strategies are critical in mitigating these risks. Patients with mild cardiac toxicity may be suitable for rechallenge, while those with more severe or persistent toxicity should generally be excluded from further osimertinib treatment. Full article
(This article belongs to the Section Oncology)
Show Figures

Figure 1

Figure 1
<p>Flow diagram of patients with non-small cell lung cancer treated at different institutions between December 2018 and April 2024.</p>
Full article ">Figure 2
<p>Changes in LVEF at baseline, during osimerinib-related HF, and after recovery (blue lines explaining for each patient, orange line is the median).</p>
Full article ">
18 pages, 9776 KiB  
Article
Papillary and Callous Scales in the Integument of Agamid Lizards (Agamidae, Sauria) as a Phenomenon of Extraordinary Development of the Corneous Layers
by Tatjana N. Dujsebayeva, Natalia B. Ananjeva, Nasrullah Rastegar-Pouyani, Awadh M. Al-Johany and Daniel A. Melnikov
Animals 2025, 15(5), 743; https://doi.org/10.3390/ani15050743 - 5 Mar 2025
Viewed by 55
Abstract
Scaled integument of six species of the genus Acanthocercus and Laudakia nupta, family Agamidae was studied using light and scanning electron microscopy. Gross observation revealed the presence of two types of modified scales in the males. The enlarged scales covered with an [...] Read more.
Scaled integument of six species of the genus Acanthocercus and Laudakia nupta, family Agamidae was studied using light and scanning electron microscopy. Gross observation revealed the presence of two types of modified scales in the males. The enlarged scales covered with an extremely thick β-corneous layer were detected in the dorsal and ventral surfaces of the tail base and on the palmar and plantar limb surfaces of all species. After detachment of the β-layer, the surface of such scales was covered with high papillae (“papillary scales”). The callous scales were found in the precloacal region of Acanthocercus species and in both precloacal and mid-ventral regions of L. nupta. Modified scales were found in some females and subadut specimens, and absent in juveniles. A prominent papillary layer characterized the dermis of both scale types. It was assumed that well-developed dermal papillae in such scales expended the total surface area of stratum germinativum and created a pool of proliferated cells in the interpapillary loops to increase the production of differentiating keratinocytes. These processes were undoubtedly associated with the formation of a thick and resistant corneous layer that distinguished both types of scales. Functional role, a taxonomic value, and analogies with normal and pathological epidermis in birds and mammals are discussed. Full article
(This article belongs to the Section Herpetology)
Show Figures

Figure 1

Figure 1
<p>View of the ventral surface of the agamid lizards studied. (<b>a</b>) <span class="html-italic">Acantrhocercus yemensis</span>, ZISP 32,062 (male, mm: L = 113.9, Lcd (regenerated) = 126.7 + 5.2). Two rows of yellowish swollen callous scales are identified in front of the cloaca (arrowhead) but the mid ventral scales show no sign of callosity. The palmar and plantar scales with a lighter color, and the ventral scales of tail base have a thick corneous layer; (<b>b</b>) <span class="html-italic">Laudakia nupta</span>, ZISP 24,661 (male, mm: L = 160.1, Lcd (regenerated) = 221.0 + 10.7 mm). Two rows of whitish callous scales with flattened surface are identified in front of the cloaca, and a small spot of similar callous scales on the central belly is well distinguished (arrowheads); the palmar and plantar scales with a darker color and slightly uneven surface, and the ventral scales of tail base are distinguishable with thick corneous layer (arrows).</p>
Full article ">Figure 2
<p>Microanatomy of unspecialized or weakly modified scales of two agamid lizards. (<b>a</b>) <span class="html-italic">Laudakia nupta</span>, the precloacal scale at the stage 1 of the resting phase of the sloughing cycle. Oberhäutchen is almost smooth on the outer scale surface and weakly serrated on the inner one (arrowhead). The arrow indicates the remnants of the clear layer above the new Oberhäutchen on the inner scale surface. The contact of epidermis and dermis is almost linear. (<b>b</b>) <span class="html-italic">Acanthocercus gregori</span>, the dorsal caudal scale at the same Stage 1. Although the contact of epidermis and dermis is almost smooth on the outer scale surface, the separate protrusions of dermis are distinguished in the top of the scale and its inner surface (arrowhead). Masson’s trichrome, parasagittal sections. Ob—Oberhäutchen; <span class="html-italic">β</span>—<span class="html-italic">β</span>-layer; m—mesos-layer; <span class="html-italic">α</span>—<span class="html-italic">α</span>-layer; LD—loose dermis, CD—compact dermis, sg—stratum germinativum; mn—melanophores.</p>
Full article ">Figure 3
<p>Microanatomy of papillary scales of the agamid lizards. (<b>a</b>) <span class="html-italic">Laudakia nupta</span>, the dermal papillae (dp) penetrated the thick <span class="html-italic">β</span>-layer (<span class="html-italic">β</span>) in semi-cross projection on the plantar scale; (<b>b</b>) <span class="html-italic">Acanthocercus gregori</span>, a row of straight dermal papillae (dp) in the dorsal scale; (<b>c</b>) <span class="html-italic">A. gregori</span>, two dermal papillae (dp) in the dorsal scale with collagen fibers extended from the loose dermis to the very tops of the papillae; (<b>d</b>) Same with <a href="#animals-15-00743-f003" class="html-fig">Figure 3</a>d papillae morphology under higher magnification. Top left, the hole from the papillae (h) in thick <span class="html-italic">β</span>-layer (<span class="html-italic">β</span>). See <a href="#animals-15-00743-f002" class="html-fig">Figure 2</a> for other abbreviations. Masson’s trichrome, parasagittal sections except of 3a where the cut went oblique.</p>
Full article ">Figure 4
<p>Scanning electron microscopy of the papillary scales from the dorsal surface of tail base of agamid lizards. (<b>a</b>) <span class="html-italic">Laudakia nupta</span>, a general view on the papillary scales. Numerous papillae (dp) are visible on the surface of the scales with the removed <span class="html-italic">β</span>—layer (<span class="html-italic">β</span>) (left). The holes in the thick <span class="html-italic">β</span>-layer were formed by cross-sectioning of the cavities produced by the invaginating papillae (right); (<b>b</b>) <span class="html-italic">L. nupta</span>, longitudinal cleavage through thick <span class="html-italic">β</span>-layer (<span class="html-italic">β</span>), showing vertical papillae (dp) covered with <span class="html-italic">α</span>-layer; (<b>c</b>) <span class="html-italic">L. nupta</span>, general view on the surface of the papillary scale without <span class="html-italic">β</span>-layer; (<b>d</b>) <span class="html-italic">L. nupta</span>, the apexes of the papillae; (<b>e</b>) <span class="html-italic">Acanthocercus gregori</span>, the papillae.</p>
Full article ">Figure 5
<p>Microanatomy of precloacal callous scales of <span class="html-italic">Laudakia nupta.</span> (<b>a</b>) secretory corn (SC) of the central callous scale of the one of the closest to cloaca rows where almost whole scale surface contributes to corneous material release; (<b>b</b>) the basal part of the callous scale with multi-layered living epidermis (E) above the stratum germinativum (sg) and the corneous material of the secretory corn (SC) that both arranged into the popular and trough regions (arrows). The dermal papillae (dp) deeply protrude the epidermis; (<b>c</b>) two dermal papillae (dp) penetrated from the epidermis; (<b>d</b>) Secretory corn of the callous scale of the row (left) distally located from the cloaca where several packs of the corneous material (SC<sub>1</sub>, SC<sub>2</sub>, SC<sub>3</sub> and molting from above) are distinguished. The corneous material of the left scale is located in its distal part while a whole scale surface contributes to the corneous material release in the right scale (the same with <a href="#animals-15-00743-f005" class="html-fig">Figure 5</a>a). Three mature epidermal generations (arrows) and part of the fourth molting (from above) surround the left secretory corn; (<b>e</b>) Secretory corn and neighboring α-layer of the epidermis showed a similarity in the structure and staining. See <a href="#animals-15-00743-f002" class="html-fig">Figure 2</a> for other abbreviations. Masson’s trichrome. Parasagittal sections.</p>
Full article ">Figure 6
<p>(<b>a</b>) habitat of <span class="html-italic">Laudakia nupta</span>, Persepolis, Fars province, Iran, April 2006. Photo by R. Nazarov; (<b>b</b>) habitat of <span class="html-italic">Acanthocercus adramitanus</span>, Dalagan, vicinity of Abha, Saudi Arabia, April 2015.</p>
Full article ">
19 pages, 9076 KiB  
Article
Functional Study of GbSMXL8-Mediated Strigolactone Signaling Pathway in Regulating Cotton Fiber Elongation and Plant Growth
by Lingyu Chen, Wennuo Xu, Lingyu Zhang, Qin Chen, Yongsheng Cai, Quanjia Chen and Kai Zheng
Int. J. Mol. Sci. 2025, 26(5), 2293; https://doi.org/10.3390/ijms26052293 - 5 Mar 2025
Viewed by 198
Abstract
The novel plant hormone strigolactones (SL) are involved significantly in plant growth and development. Its key members SMXL6, 7, 8 can modulate SL signal reception and response negatively and can regulate plant branching remarkably. There are relatively scarce studies of cotton [...] Read more.
The novel plant hormone strigolactones (SL) are involved significantly in plant growth and development. Its key members SMXL6, 7, 8 can modulate SL signal reception and response negatively and can regulate plant branching remarkably. There are relatively scarce studies of cotton SMXL gene family, and this study was carried out to clarify the role of GbSMXL8 in cotton fiber development. Phylogenetic analysis identified 48 cotton SMXL genes, which were divided into SMXL-I (SMXL 1, 2), SMXL-II (SMXL 3) and SMXL-III (SMXL6, 7, 8) groups. The results of the cis-element analysis indicated that the SMXL gene could respond to hormones and the environment to modulate cotton growth process. A candidate gene GbSMXL8 was screened out based on the expression difference in extreme varieties of Gossypium barbadense. Tissue-specific analysis indicated that GbSMXL8 was mainly expressed in roots, 20D, 25D, and 35D and was involved in SL signaling pathways. In vitro ovule culture experiments showed that exogenous SLs (GR24) could promote the fiber elongation of G. barbadense, and GbSMXL8 expression was increased after GR24 treatment, indicating that GbSMXL8 was specifically responsive to GR24 in regulating fiber growth. GbSMXL8 knockout resulted in creased length and number of epidermal hairs and the length of fiber, indicating the interference role of GbSMXL8 gene with the development of cotton fiber. The GbSMXL8 transgenic plant was detected with a higher chlorophyll content and photosynthetic rate than those of the control plant, producing a direct impact on plant growth, yield, and biomass accumulation. GbSMXL8 gene knockout could increase plant height, accelerate growth rate, and lengthen fiber length. Intervening GbSMXL8 may mediate cotton growth, plant type formation and fiber elongation. In conclusion, the present study uncovers the function of GbSMXL8-mediated SL signal in cotton, providing theoretical insight for future breeding of new cotton varieties. Full article
(This article belongs to the Special Issue Research on Plant Genomics and Breeding: 2nd Edition)
Show Figures

Figure 1

Figure 1
<p>Phylogenetic tree of SMXL protein in <span class="html-italic">G. arboreum</span>, <span class="html-italic">G. barbadense</span>, <span class="html-italic">G. raymond</span>, <span class="html-italic">G. hirsutum</span>, <span class="html-italic">Arabidopsis thaliana</span>, and <span class="html-italic">Oryza sativa</span> L. Alignment of SMXL amino acid sequences was completed using ClustalW, and the phylogenetic tree was constructed by MEGA 7.0 using adjacent linkage method, with 1000 repeats. Gh, Gb, Ga, Gr, Os, and At represent <span class="html-italic">G. hirsutum</span>, <span class="html-italic">G. barbadense</span>, <span class="html-italic">G. raymond</span>, <span class="html-italic">G. raymond</span>, <span class="html-italic">Oryza sativa</span> L., and <span class="html-italic">Arabidopsis thaliana</span>.</p>
Full article ">Figure 2
<p>Genetic structure and conserved domains of SMXL protein in four cotton species.</p>
Full article ">Figure 3
<p>Analysis of cis-acting elements of SMXL in <span class="html-italic">G. hirsutum</span>, <span class="html-italic">G. barbadense</span>, <span class="html-italic">G. Raymond</span>, and <span class="html-italic">G. arboreum</span>.</p>
Full article ">Figure 4
<p>Expression analysis of SMXL during fiber development of sea island cotton. (<b>A</b>): Transcriptome expression heat map of different varieties of <span class="html-italic">G. barbadense</span>. (<b>B</b>): Relative expression level of <span class="html-italic">GbSMXL8</span> in different tissues of <span class="html-italic">G. barbadense</span>.</p>
Full article ">Figure 5
<p>Positive regulation of polygalactone on the fiber development of <span class="html-italic">G. barbadense</span>. (<b>A</b>): Cotton fiber phenotype (collected at 1 DPA) cultured in vitro for 5, 10, 15, 20, 25, 30 days in a medium containing 15 μM SL synthetic analog GR24, 15 μM SL biosynthesis inhibitor Tis 108, and controls; (<b>B</b>): Average fiber length; (<b>C</b>): SL epi-5DS content in ovules at varied growth stages; (<b>D</b>): relative expression of GbSMXL8 in cotton fibers treated with 15 μM mGR24 or 15 μM Tis 108 for 5, 10, 15, 20, 25, and 30 days; (<b>E</b>): total fresh weight of ovule; (<b>F</b>): total ovule dry weight. * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.01; *** <span class="html-italic">p</span> &lt; 0.001; **** <span class="html-italic">p</span> &lt; 0.0001. Wild type (A130768).</p>
Full article ">Figure 6
<p>Gene editing SMXL8 target analysis and identification. (<b>A</b>): Cloning of double target sgRNA of <span class="html-italic">GbSMXL8</span> gene; (<b>B</b>): <span class="html-italic">GbSMXL8</span> gene; (<b>C</b>): PCR product of double target sgRNA Agrobacterium; (<b>D</b>): PCR product identification of transgenic plant; (<b>E</b>): Two sgRNA positions of <span class="html-italic">GbSMXL8</span> (<b>F</b>): Sequencing of SmXL8 edited plant.</p>
Full article ">Figure 7
<p><span class="html-italic">GbSMXL8</span> inhibited stem epidermal hair growth (<b>A</b>): <span class="html-italic">GbSMXL8</span> edited cotton stem and leaf margin epidermal hair; (<b>B</b>): <span class="html-italic">GbSMXL8</span> edited cotton epidermal hair average length; (<b>C</b>): <span class="html-italic">GbSMXL8</span> edited cotton epidermal hair number. * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.01;. WT (ZM 49).</p>
Full article ">Figure 8
<p>Phenotypic and physiological characterization of transgenic cotton plants. (<b>A</b>) Net photosynthetic rate (Pn) in leaves of wild-type (WT) and transgenic cotton lines. (<b>B</b>) Stomatal conductance (Gs) in leaves of WT and transgenic lines. (<b>C</b>) Transpiration rate (Tr) in leaves of WT and transgenic lines. (<b>D</b>) Intercellular CO<sub>2</sub> concentration (Ci) in leaves of WT and transgenic lines. (<b>E</b>) Chlorophyll content in leaves of WT and transgenic lines. Notes:WT: Wild-type control (cultivar ZM 49). Statistical significance: * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.01; *** <span class="html-italic">p</span> &lt; 0.001 (Student’s <span class="html-italic">t</span>-test). All data represent mean ± SD (<span class="html-italic">n</span> = 3 biological replicates).</p>
Full article ">Figure 9
<p>Effect of transgenic plants on fiber development. (<b>A</b>): WT, smxl8 transgenic plant fibers; (<b>B</b>): smxl8 transgenic cotton leaf mature fiber length. * <span class="html-italic">p</span> &lt; 0.05; WT (ZM 49).</p>
Full article ">
17 pages, 602 KiB  
Systematic Review
From Rash Decisions to Critical Conditions: A Systematic Review of Dermatological Presentations in Emergency Departments
by Abdullah S. Algarni, Safinaz M. Alshiakh, Sara M. Alghamdi, Mohammed A. Alahmadi, Abdulah W. Bokhari, Samar N. Aljubayri, Waad M. Almutairy, Najwa M. Alfahmi and Ramy Samargandi
Diagnostics 2025, 15(5), 614; https://doi.org/10.3390/diagnostics15050614 - 4 Mar 2025
Viewed by 225
Abstract
Background: Dermatological emergencies are critical conditions requiring immediate attention due to their potential to escalate into life-threatening scenarios. Accurate diagnosis and timely management are essential to prevent severe complications, including systemic involvement and mortality. This systematic review summarizes findings on dermatological emergencies in [...] Read more.
Background: Dermatological emergencies are critical conditions requiring immediate attention due to their potential to escalate into life-threatening scenarios. Accurate diagnosis and timely management are essential to prevent severe complications, including systemic involvement and mortality. This systematic review summarizes findings on dermatological emergencies in emergency departments (EDs), focusing on diagnostic accuracy, hospitalization rates, systemic complications, and management strategies. Methods: A systematic literature review of studies on dermatological emergencies was conducted, encompassing 24 prospective and retrospective cohort studies, cross-sectional studies, and descriptive analyses. The review included diverse patient populations, examining dermatological presentations, diagnostic methods, treatment strategies, hospitalization rates, and adverse outcomes. Key outcome measures such as diagnostic accuracy, complications, mortality rates, and re-visit frequencies were analyzed. Results: The studies revealed high diagnostic accuracy, particularly in in-person evaluations, with teledermatology showing slightly lower but reliable rates. Systemic complications, including severe drug reactions, bacterial infections, and autoimmune diseases, were common causes of hospitalization. Mortality rates varied, with conditions such as toxic epidermal necrolysis showing the highest risk. Hospitalization rates averaged 4.52%, and re-visit rates ranged from 1% to 6.5%. The results also highlighted the impact of environmental factors and seasonal trends on dermatological presentations. Conclusions: Dermatological emergencies pose significant challenges in emergency care. High diagnostic accuracy and effective management strategies are crucial in preventing severe outcomes. Timely diagnosis, careful management of systemic complications, and teledermatology play critical roles in improving care. Future research should focus on standardized management protocols, telemedicine applications, and the influence of environmental and demographic factors to enhance patient outcomes. Full article
(This article belongs to the Section Clinical Diagnosis and Prognosis)
Show Figures

Figure 1

Figure 1
<p>The PRISMA figures showing the steps to choose the studies for systematic review.</p>
Full article ">
12 pages, 1428 KiB  
Article
First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis
by Yan Xiang, Meiling Zhang, Qian Wang, Jingwen Liu, Lulin Zeng, Ao Sun and Kaihua Lu
Curr. Oncol. 2025, 32(3), 148; https://doi.org/10.3390/curroncol32030148 - 4 Mar 2025
Viewed by 212
Abstract
Background: HER2 mutations are rare driver events in advanced NSCLC, with limited relief from current targeted therapies. This study aimed to characterize the molecular features of HER2-mutant NSCLC and to evaluate the clinical efficacy of pyrotinib-based combination therapy as a first-line treatment, providing [...] Read more.
Background: HER2 mutations are rare driver events in advanced NSCLC, with limited relief from current targeted therapies. This study aimed to characterize the molecular features of HER2-mutant NSCLC and to evaluate the clinical efficacy of pyrotinib-based combination therapy as a first-line treatment, providing evidence for optimizing treatment strategies. Methods: NSCLC patients diagnosed at Jiangsu Province People’s Hospital from 2016 to 2024 were enrolled. HER2-positive cases were screened by IHC/FISH and further profiled by NGS. Treatment response was assessed by RECIST 1.1, and survival analysis was performed using Kaplan–Meier and log-rank tests. Results: Among 144 HER2-mutant NSCLC cases confirmed by NGS, 10 insertion mutations, 26 missense mutations, and 2 fusion mutations were identified. The most common mutation was the exon 20 p.A775_G776insYVMA (47.9%), and TP53 was the most frequent co-mutation (10.4%). In terms of efficacy, the pyrotinib-based combination therapy demonstrated significant clinical benefit, with an ORR of 33.3%, DCR of 95.2%, median PFS (mPFS) of 11.3 months (95% CI: 10.27–12.26), and median OS (mOS) of 21.0 months (95% CI: 18.00–23.94). Subgroup analysis revealed no significant impact of mutation subtype or co-mutation status on the treatment efficacy, but patients with brain metastases had a significantly worse prognosis than those without metastasis (mPFS: 5.1 vs. 12.9 months, p < 0.01; mOS: 9.3 vs. 26.5 months, p < 0.01). All TRAEs were grade 1–3 (any grade: 90.5%; grade 3: 14.3%), with the most common TRAE being diarrhea (any grade: 85.7%; grade 3: 9.5%). Conclusions: Pyrotinib-based combination therapy is a feasible first-line treatment for HER2-mutant NSCLC, demonstrating significant survival benefits and manageable toxicity. However, brain metastasis patients require enhanced comprehensive management. Full article
(This article belongs to the Section Thoracic Oncology)
Show Figures

Figure 1

Figure 1
<p>Molecular characteristic of HER2 mutations. (Percentages in the right part of <a href="#curroncol-32-00148-f001" class="html-fig">Figure 1</a> total 99.9% due to rounding).</p>
Full article ">Figure 2
<p>Treatment response and its proportions for 21 patients.</p>
Full article ">Figure 3
<p>Survival curves of 21 patients treated with pyrotinib combined with chemotherapy. (<b>A</b>): PFS; (<b>B</b>): OS.</p>
Full article ">Figure 4
<p>Kaplan–Meier survival curves showing PFS and OS in different groups. (<b>A</b>) Mutation subtypes and PFS: No significant difference between YVMA and non-YVMA groups (<span class="html-italic">p</span> = 0.37). (<b>B</b>) Co-mutation and PFS: No significant difference between positive and negative groups (<span class="html-italic">p</span> = 0.94). (<b>C</b>) Brain metastasis and PFS: Significantly lower in patients with brain metastasis (<span class="html-italic">p</span> = 0.001). (<b>D</b>) Brain metastasis and OS: Significantly lower in patients with brain metastasis (<span class="html-italic">p</span> = 0.002). (* indicates a statistically significant difference in <span class="html-italic">p</span>-value.)</p>
Full article ">
21 pages, 6601 KiB  
Article
Production of Aloe vera Phytoplacenta Extract and Potential Applications in Skincare
by Seung Min Jung, Hye-In Kim, Soo-Yun Kim, Sung Joo Jang, Hyo Hyun Seo, Jeong Hun Lee, Ju-Duck Kim, Won Kyong Cho and Sang Hyun Moh
Life 2025, 15(3), 397; https://doi.org/10.3390/life15030397 - 3 Mar 2025
Viewed by 140
Abstract
Aloe vera has garnered significant scientific and commercial attention due to its multifaceted therapeutic and cosmetic potential. This study aimed to investigate the biological effects and molecular mechanisms of Aloe vera phytoplacenta extract (AVPE) on HaCaT cells and skin health. To achieve this, [...] Read more.
Aloe vera has garnered significant scientific and commercial attention due to its multifaceted therapeutic and cosmetic potential. This study aimed to investigate the biological effects and molecular mechanisms of Aloe vera phytoplacenta extract (AVPE) on HaCaT cells and skin health. To achieve this, we investigated AVPE, produced using advanced in vitro cell culture techniques, and its effects on HaCaT cells. At 2% concentration, AVPE demonstrated remarkable biological effects, increasing AQP3 protein expression by 120% and healing area fourfold while simultaneously reducing COX-2 messenger RNA (mRNA) by 43% and iNOS mRNA by 48%. An AVPE-containing product notably reduced facial skin temperature to 24.9 °C compared to 32.3 °C for the control product. RNA-sequencing (RNA-seq) analysis of transcriptional changes in HaCaT cells after AVPE treatment revealed 14 upregulated and 58 downregulated RNAs. Upregulated processes included response to hydrogen peroxide and muscle cell migration, while downregulated processes involved cell–cell adhesion and synaptic transmission. Pathway analysis further highlighted significant metabolic changes, including upregulation of pentose phosphate and galactose metabolism pathways and downregulation of the leishmaniasis and GABAergic synapse pathways. In addition, gene expression data indicated subtle changes in epidermal differentiation genes, modulation of inflammatory markers, and alterations in genes related to cell signaling and skin-specific functions. Our comprehensive findings underscore AVPE’s potential in enhancing skin healing, regulating temperature, and modulating cellular processes. Full article
(This article belongs to the Special Issue Advances in the Biomedical Applications of Plants and Plant Extracts)
Show Figures

Figure 1

Figure 1
<p>Production of <span class="html-italic">Aloe vera</span> phytoplacenta extract (AVPE) from flower to final product: (<b>A</b>) Close-up image of the <span class="html-italic">Aloe vera</span> flower, highlighting the structure and arrangement of the petals. (<b>B</b>) Dissected parts of the <span class="html-italic">Aloe vera</span> flower, including petals and stamens. (<b>C</b>) Cross-sectional view of the phytoplacenta, with the central part highlighted by a red dotted circle. (<b>D</b>) Multiple explants of <span class="html-italic">Aloe vera</span> phytoplacenta cultured in vitro. (<b>E</b>) The induced callus on MS medium. (<b>F</b>) Preparation of suspension cell culture of <span class="html-italic">Aloe vera</span> phytoplacenta cells in liquid medium. (<b>G</b>) Transfer of cultured cells to a 3 L bioreactor. (<b>H</b>) One week after culture in the bioreactor. (<b>I</b>) Industrial bioreactors used for the large-scale production of AVPE. (<b>J</b>) Drying cells using a freeze-dryer. (<b>K</b>) Final product of the <span class="html-italic">Aloe vera</span> phytoplacenta freeze-dried cells, highlighting its texture and appearance.</p>
Full article ">Figure 2
<p>Cell viability of HaCaT cells treated with AVPE assessed by CCK-8 assay: control group with no treatment; 0.5%: HaCaT cells treated with 0.5% AVPE; 1%: HaCaT cells treated with 1% AVPE; 2%: HaCaT cells treated with 2% AVPE. The graph shows the percentage of viable cells for each treatment condition relative to the control.</p>
Full article ">Figure 3
<p>AVPE enhances skin moisturizing through increased AQP3 expression. Results of (<b>A</b>) Western blot analysis of AQP3 and β-actin protein levels in skin treated with different concentrations of AVPE (0.05%, 0.1%, 0.5%, 1%, 2%, 5%, and 7%) compared to control (C) using distilled water. Glyceryl glucoside (1%) was used as a positive control. β-actin served as a loading control. (<b>B</b>) Bar graph depicting the relative AQP3 protein expression levels in skin treated with AVPE. The expression level increases significantly in a dose-dependent manner, with a maximum 120% increase observed at the 2% AVPE concentration. Error bars represent standard deviation. *, **, and *** indicate <span class="html-italic">p</span> &lt; 0.05, <span class="html-italic">p</span> &lt; 0.01, and <span class="html-italic">p</span> &lt; 0.001, respectively.</p>
Full article ">Figure 4
<p>AVPE enhances wound healing. (<b>A</b>) Images showing the wound-healing process at time points T0 and T16 for skin treated with different concentrations of AVPE (0.5%, 1%, and 2%) compared to control (C). (<b>B</b>) Bar graph illustrating the percentage of the healing area in skin treated with AVPE. The healing area significantly increases in a dose-dependent manner, with a fourfold increase observed at the 2% AVPE concentration. Error bars represent standard deviation. * and ** indicate <span class="html-italic">p</span> &lt; 0.05 and <span class="html-italic">p</span> &lt; 0.01, respectively.</p>
Full article ">Figure 5
<p>AVPE exhibits anti-inflammatory effects in UV-exposed skin. (<b>A</b>) Relative <span class="html-italic">COX-2</span> mRNA expression levels in UV-exposed skin treated with different concentrations of AVPE (0.5%, 1%, and 2%) compared to untreated control (-). (<b>B</b>) Relative <span class="html-italic">iNOS</span> mRNA expression levels in UV-exposed skin treated with different concentrations of AVPE (0.5%, 1%, and 2%) compared to untreated control (-). Data are presented as mean ± SD. ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001 vs. untreated control.</p>
Full article ">Figure 6
<p>Effects of AVPE-containing test product and control product on facial skin temperature. (<b>A</b>) Bar graph showing the facial skin temperature (°C) of subjects before heating, after heating (before use), and after use of the test product (yellow bars) and control product (gray bars), with significant differences indicated by asterisks (*** <span class="html-italic">p</span> &lt; 0.001) and hash marks (<sup>###</sup> <span class="html-italic">p</span> &lt; 0.001). (<b>B</b>) Thermal images of a representative subject (ID number TEK1202201) showing facial skin temperature before heating, after heating (before use), and after use of the test product (yellow labels) and control product (gray labels). The thermal images visually demonstrate the changes in facial skin temperature corresponding to the conditions shown in panel (<b>A</b>). Before heating: test product 34 °C, control product 34 °C; after heating: test product 37.20 °C, control product 37.20 °C; after use: test product 25.20 °C, control product 33.20 °C.</p>
Full article ">Figure 7
<p>Results of the analysis of differential gene expression and RNA categorization: (<b>A</b>) Volcano plot of differential gene expression. Green dots represent downregulated RNAs (73 RNAs), gray dots represent non-significant RNAs, and red dots represent upregulated RNAs (23 RNAs). The x-axis represents the −log2 (fold change (FC)), and the y-axis represents the −log10 (<span class="html-italic">p</span>-value). Notable RNAs are labeled. (<b>B</b>) Number of RNAs according to categories. The categories include antisense RNA, long noncoding RNA, miscellaneous RNA, mRNA, ncRNA, and noncoding RNA. (<b>C</b>) Number of DERs derived from the same gene. Green and red colored bars indicate down- and upregulated RNAs, respectively.</p>
Full article ">Figure 8
<p>Gene ontology (GO) enrichment analysis of DERs. The identified enriched GO terms for upregulated RNAs (<b>A</b>) and downregulated RNAs (<b>B</b>). The dot plot shows the significantly enriched GO terms in the categories of biological process (BP), cellular component (CC), and molecular function (MF) for upregulated genes. The color of the dots represents the −log10 (<span class="html-italic">p</span>-value), and the size of the dots represents the number of genes associated with each GO term.</p>
Full article ">Figure 9
<p>DERs in KEGG and Reactome pathways. The enriched pathways associated with upregulated RNAs (<b>A</b>) and downregulated RNAs (<b>B</b>). The x-axis represents the number of RNAs, while the y-axis represents the pathways. The color gradient from green to red indicates the −log10 (<span class="html-italic">p</span>-value), with red representing higher significance. The size of the dots corresponds to the RNA count within each pathway.</p>
Full article ">Figure 10
<p>Effect of AVPE on gene expression related to epidermal differentiation, inflammation, and oxidative stress response. (<b>A</b>) Epidermal differentiation genes: <span class="html-italic">IVL</span>, <span class="html-italic">FLG2</span>, <span class="html-italic">FLG</span>, <span class="html-italic">DSC3</span>, <span class="html-italic">KRT10</span>, <span class="html-italic">KRT6A</span>, <span class="html-italic">KRT15</span>, and <span class="html-italic">DSG2</span>. (<b>B</b>) Inflammation genes: <span class="html-italic">TNF</span>, <span class="html-italic">IL1B</span>, and <span class="html-italic">IL6</span>, and oxidative stress gene: <span class="html-italic">GPX4</span>. The gene expression data were obtained from RNA-seq analysis, and normalized values were used for the comparison.</p>
Full article ">Figure 11
<p>Effect of AVPE on expression of genes related to cell signaling pathways and other functions. (<b>A</b>) Genes related to cell signaling pathways: <span class="html-italic">MAPK14</span>, <span class="html-italic">ATM</span>, <span class="html-italic">MDM2</span>, <span class="html-italic">MMP14</span>, <span class="html-italic">CHKA</span>, <span class="html-italic">IRF2BP2</span>, <span class="html-italic">KLF2</span>, and <span class="html-italic">RELA</span>. (<b>B</b>) Genes related to other functions: <span class="html-italic">H2AFX</span>, <span class="html-italic">TGM1</span>, <span class="html-italic">TGM2</span>, <span class="html-italic">RDH16</span>, <span class="html-italic">KLK14</span>, <span class="html-italic">DUSP10</span>, <span class="html-italic">CAPN1</span>, and <span class="html-italic">CYP2E1</span>. The gene expression data were obtained from RNA-seq analysis, and normalized values were used for the comparison.</p>
Full article ">
12 pages, 1903 KiB  
Article
Efficacy of a New Non-Invasive System Delivering Microwave Energy for the Treatment of Abdominal Adipose Tissue: Results of an Immunohistochemical Study
by Elena Zappia, Stefano Bennardo, Gaia Fasano, Valerio Raffaele, Tiziano Zingoni, Laura Pieri, Lara Ronconi, Paolo Bonan, Luigi Bennardo, Antonella Tammaro, Klaus Hoffmann and Steven Paul Nisticò
Cosmetics 2025, 12(2), 42; https://doi.org/10.3390/cosmetics12020042 - 3 Mar 2025
Viewed by 144
Abstract
Unwanted abdominal fat is a common aesthetic concern treated through various interventions, including surgical and energy-based devices, often leading to inconsistent results. This study aimed to evaluate the feasibility of a localized, non-invasive microwave (MW) device for preferential heating of subcutaneous adipose tissue [...] Read more.
Unwanted abdominal fat is a common aesthetic concern treated through various interventions, including surgical and energy-based devices, often leading to inconsistent results. This study aimed to evaluate the feasibility of a localized, non-invasive microwave (MW) device for preferential heating of subcutaneous adipose tissue using a controlled electromagnetic field. Five female volunteers scheduled for abdominoplasty were enrolled, each undergoing a single MW treatment session five days prior to surgery. Histological analyses of adipose tissue and skin samples were conducted using Hematoxylin and Eosin staining and immunohistochemistry for Perilipin-1 and CD68. Epidermal and dermal layers remained unaffected, as evidenced by unaltered morphology in treated samples. In contrast, the absence of Perilipin-1 expression in disrupted fat cell membranes indicated adipocyte non-viability and irreversible injury. Inflammatory responses, including CD68-positive macrophages surrounding damaged adipocytes, were observed, suggesting the activation of the monocyte/macrophage system for the clearance of adipocyte residues. Microscopic and immunohistochemical findings demonstrate the effectiveness of the MW device in reducing subcutaneous fat. This study also discussed the underlying mechanisms involved in macrophage recruitment and the removal of adipocyte residues. Full article
Show Figures

Figure 1

Figure 1
<p>The treated sample’s epidermis (<b>B</b>) does not differ from the control sample (<b>A</b>) in any way; no changes can be noticed in epidermis immediately after treatment (<b>B</b>) because of skin cooling performed by the device handpiece. Additionally, the dermis’s collagen seems to be strongly colored as a result of the heat-induced shrinkage or tightening of the collagen, which increases eosinophilia. ((<b>A</b>,<b>B</b>) 10× Magnifications).</p>
Full article ">Figure 2
<p>In the adipose tissue immediately after treatment (<b>B</b>,<b>C</b>), the following are observed: wavy adipocitary membranes (weakening of membranes), some rupture of the plasma membrane, and initial hyperemia with dilation of blood vessels (<b>C</b>). In the control sample (<b>A</b>), packed adipocytes. ((<b>A</b>,<b>B</b>) 10× Magnification; (<b>C</b>), 40× Magnification).</p>
Full article ">Figure 3
<p>Adipocytes positive to Perilipin-1 in the control sample (<b>A</b>). After treatment with ONDA (<b>B</b>,<b>C</b>), adipocyte membranes are interrupted with negative Perilipin-1 results (non-viable adipocytes) (1.5–1.8 cm from the epidermis) (<b>B</b>); Perilipin-1 is still present in the wavy adipocitary membranes (more than 2 cm from the epidermis) (<b>C</b>). ((<b>A</b>–<b>C</b>), 40× Magnification).</p>
Full article ">Figure 4
<p>CD68 positive cells (<b>*</b>) between adipocytes, with broken or wavy membranes after treatment with ONDA (<b>A</b>,<b>B</b>) ((<b>A</b>,<b>B</b>), 40× Magnification).</p>
Full article ">
34 pages, 2242 KiB  
Review
Druggable Molecular Networks in BRCA1/BRCA2-Mutated Breast Cancer
by Francesca Pia Carbone, Pietro Ancona, Stefano Volinia, Anna Terrazzan and Nicoletta Bianchi
Biology 2025, 14(3), 253; https://doi.org/10.3390/biology14030253 - 2 Mar 2025
Viewed by 356
Abstract
Mutations in the tumor suppressor genes BRCA1 and BRCA2 are associated with the triple-negative breast cancer phenotype, particularly aggressive and hard-to-treat tumors lacking estrogen, progesterone, and human epidermal growth factor receptor 2. This research aimed to understand the metabolic and genetic links behind [...] Read more.
Mutations in the tumor suppressor genes BRCA1 and BRCA2 are associated with the triple-negative breast cancer phenotype, particularly aggressive and hard-to-treat tumors lacking estrogen, progesterone, and human epidermal growth factor receptor 2. This research aimed to understand the metabolic and genetic links behind BRCA1 and BRCA2 mutations and investigate their relationship with effective therapies. Using the Cytoscape software, two networks were generated through a bibliographic analysis of articles retrieved from the PubMed-NCBI database. We identified 98 genes deregulated by BRCA mutations, and 24 were modulated by therapies. In particular, BIRC5, SIRT1, MYC, EZH2, and CSN2 are influenced by BRCA1, while BCL2, BAX, and BRIP1 are influenced by BRCA2 mutation. Moreover, the study evaluated the efficacy of several promising therapies, targeting only BRCA1/BRCA2-mutated cells. In this context, CDDO-Imidazolide was shown to increase ROS levels and induce DNA damage. Similarly, resveratrol decreased the expression of the anti-apoptotic gene BIRC5 while it increased SIRT1 both in vitro and in vivo. Other specific drugs were found to induce apoptosis selectively in BRCA-mutated cells or block cell growth when the mutation occurs, i.e., 3-deazaneplanocin A, genistein or daidzein, and PARP inhibitors. Finally, over-representation analysis on the genes highlights ferroptosis and proteoglycan pathways as potential drug targets for more effective treatments. Full article
(This article belongs to the Special Issue Advances in Biological Breast Cancer Research)
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Scheme of progressive steps for the selection of articles including all criteria: <span class="html-italic">BRCA</span> mutations, modulated genes and drug treatments for network creation.</p>
Full article ">Figure 2
<p>Link between apoptosis and genomic instability in BC cells. For <span class="html-italic">BRCA2</span>, we analyzed studies and evaluated the most impacted genes. In this case, <span class="html-italic">BRCA2</span> was represented as the “node” in the blue octagon, whilst the other genes were the “edges” in purple rectangles. Flat-tipped lines represent downregulation, whereas pointed arrows represent upregulation, and the brown lines are representative for phytoestrogen treatment.</p>
Full article ">Figure 3
<p>Network of correlation between altered genes by <span class="html-italic">BRCA1</span> mutation and treatments. (<b>A</b>) We used colors to graphically highlight <span class="html-italic">BRCA1</span> (light blue octagon) and the deregulated genes (white rectangles). <span class="html-italic">BRCA1</span> was represented as the “node”, whereas the other genes were named “edges”. Flat-tipped lines represent the downregulation of gene expression, while the pointed arrows represent upregulation. The colored lines represent the different treatments used on <span class="html-italic">BRCA1</span>-mutated cell lines and their effect on gene expression. Dashed lines are used to depict secondary interactions whereas the continuous lines portray primary and direct interactions. (<b>B</b>) Highlighting of the genes modulated by therapies.</p>
Full article ">Figure 4
<p>Bar chart of the top 20 KEGG pathways. The image was created with Python v.3.13.1 (matplotlib).</p>
Full article ">
12 pages, 2748 KiB  
Article
Clinical Significance of Fragile X Syndrome 2 (FXR2) in Breast Cancer
by Ohud A. Alsalmi, Abrar I. Aljohani, Shahad M. Almutairi, Rana O. Alsufyani, Abdulrahman R. Alrubayee, Khalid J. Alzahrani, Ghaida E. Alkhammash, Hessa M. Aljuaid, Hanan S. Alghamdi and Fouzeyyah A. Alsaeedi
Genes 2025, 16(3), 302; https://doi.org/10.3390/genes16030302 - 1 Mar 2025
Viewed by 237
Abstract
Background: The fragile X protein family comprises three members: the fragile X syndrome protein (FMRP) and its structural homologs, fragile X syndrome 1 and 2 (FXR1 and FXR2). FMRP has a significant role in controlling the genesis and progression of various forms [...] Read more.
Background: The fragile X protein family comprises three members: the fragile X syndrome protein (FMRP) and its structural homologs, fragile X syndrome 1 and 2 (FXR1 and FXR2). FMRP has a significant role in controlling the genesis and progression of various forms of human cancer. However, studies on the prognostic significance of FXR2 in cancer are scarce. Thus, this study aimed to investigate the clinicopathological significance of FXR2, a member of the FMRP family, in primary breast cancer (BC). Methods: A total of 100 formalin-fixed paraffin-embedded (FFPE) tissue blocks from invasive BC cases were collected from King Abdulaziz Hospital in Saudi Arabia. Immunohistochemistry (IHC) was used to assess FXR2 protein expression in the BC tissues, and the results were correlated with clinicopathological parameters, such as tumor grade, tumor size and hormone receptor status. Additionally, the association between clinicopathological features and FXR2 mRNA expression was assessed using the BC Gene-Expression Miner v5.0 tool on all publicly available DNA microarray (n = 10,872) and RNA sequence (n = 4421) data to validate the results. Results: FXR2 protein expression was significantly associated with human epidermal growth factor 2 (HER2) negativity (p = 0.010) and low Ki67 (p < 0.001). Both DNA microarray and RNA sequence data showed that HER2 negativity was strongly linked to high levels of FXR2 mRNA. High FXR2 mRNA levels were also correlated with hormone receptor negativity and mutated p53. Conclusions: This study suggests that FXR2 may have indirect clinical significance in BC. However, further studies are warranted to deepen our understanding of the association between FXR2 and other clinicopathological parameters, which could lead to improved diagnostic, treatment, and prognostic strategies for BC patients. Full article
(This article belongs to the Section Human Genomics and Genetic Diseases)
Show Figures

Figure 1

Figure 1
<p>Light microscope images (magnification ×40) show the immunohistochemical protein expression of FXR2 in breast tissue. FXR2 expression was observed in the cytoplasm. (<b>A</b>) Negative control of colon tissue without FXR2 antibody. (<b>B</b>) Colon cancer sample used as a positive control. (<b>C</b>) Invasive breast carcinoma showing low expression. (<b>D</b>) Invasive breast carcinoma showing high expression. High expression is defined by an H-score cutoff point of 110 or more, based on the median for dichotomization.</p>
Full article ">Figure 2
<p><span class="html-italic">FXR2</span> mRNA expression in relation to breast cancer clinical features based on DNA microarray data. Correlation of <span class="html-italic">FXR2</span> mRNA with (<b>A</b>) age, (<b>B</b>) nodal status, (<b>C</b>) ER (IHC), (<b>D</b>) PR (IHC), (<b>E</b>) HER2 (IHC), (<b>F</b>) PAM50 molecular subtypes (more significant in basal-like and luminal A subgroup), (<b>G</b>) P53 gene status (IHC), (<b>H</b>) P53 gene status (sequence-based) and (<b>I</b>) P53 gene status (GES).</p>
Full article ">Figure 3
<p><span class="html-italic">FXR2</span> mRNA expression in relation to breast cancer clinical features based on RNA sequence data. Correlation of <span class="html-italic">FXR2</span> mRNA with (<b>A</b>) age, (<b>B</b>) nodal status, (<b>C</b>) ER (IHC), (<b>D</b>) PR (IHC), (<b>E</b>) HER2 (IHC), and (<b>F</b>) PAM50 molecular subtypes (more significant in luminal B and basal-like subgroups).</p>
Full article ">Figure 4
<p>A summary of the effect of silencing the RNP complex composed of RBPs on tumor growth.</p>
Full article ">
14 pages, 1819 KiB  
Article
Ultraviolet B Exposure Does Not Influence the Expression of YAP mRNA in Human Epidermal Keratinocytes—Preliminary Study
by Igor Aleksander Bednarski, Izabela Dróżdż, Magdalena Ciążyńska, Karolina Wódz, Joanna Narbutt and Aleksandra Lesiak
Biomedicines 2025, 13(3), 596; https://doi.org/10.3390/biomedicines13030596 - 1 Mar 2025
Viewed by 178
Abstract
Background: The causal relationship between exposure to ultraviolet radiation and the development of skin cancers requires constant research for possible orchestrating mechanisms. In recent years, the Hippo pathway, along with its effector protein YAP, became implicated in cutaneous carcinogenesis; however, Hippo pathway regulation [...] Read more.
Background: The causal relationship between exposure to ultraviolet radiation and the development of skin cancers requires constant research for possible orchestrating mechanisms. In recent years, the Hippo pathway, along with its effector protein YAP, became implicated in cutaneous carcinogenesis; however, Hippo pathway regulation by ultraviolet radiation has not been described thoroughly. In order to address this issue, we focused on how different doses of ultraviolet B affect Hippo signaling pathway components and its upstream regulators, JNK1/2 and ABL1, in human keratinocytes. Additionally, we decided to determine how silencing of YAP influences Hippo pathway component expression. Methods: Primary epidermal keratinocytes were irradiated using UVB lamps with increasing doses of ultraviolet B radiation (including 311 nm UVB). Real-time PCR was used to determine the mRNA levels of each investigated gene. The experiment was then performed after YAP silencing using siRNA transfection. Additionally, we determined the mRNA expression of Hippo pathway components in an A431 cSCC cell line. Results: We observed that YAP mRNA expression in the A431 cell line was insignificant in comparison to control, while in the case of LATS1/2, a significant increase was noted. UVB irradiation did not change the levels of YAP mRNA expression in human epidermal keratinocytes. LATS1, LATS2, ABL1 and MAP4K4 mRNA expression was significantly upregulated after UVB irradiation in non-YAP-silenced keratinocytes in a dose-dependent manner, while after YAP silencing, only LATS2 and ABL1 showed significant mRNA upregulation. The 311 nm UVB irradiation resulted in significant, dose-dependent mRNA upregulation in non-YAP-silenced keratinocytes for LATS1, ABL1 and MAP4K4. After YAP silencing, a significant change in mRNA expression was present only in the case of ABL1. Conclusions: YAP mRNA expression does not significantly increase after exposure to UVB; however, it upregulates the expression of its proven (LATS1/2, JNK1/2) regulators, suggesting that in real-life settings, UV-induced dysregulation of the Hippo pathway may not be limited to YAP. Full article
Show Figures

Figure 1

Figure 1
<p>mRNA expression of YAP and its regulators in A431 cell line. Data presented as fold change (columns) with geometric standard deviations (bars). Asterisks above columns indicate level of statistical significance (ns—not significant, * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.001) in comparison to controls.</p>
Full article ">Figure 2
<p>YAP fold change alterations in primary epidermal keratinocytes after exposure to different doses of UVB (<b>A</b>) and 311 nm UVB (<b>B</b>). Data presented as fold change (columns) with geometric standard deviations (bars) (ns—not significant).</p>
Full article ">Figure 3
<p>mRNA expression of studied Hippo pathway regulators: LATS1 (<b>A</b>), LATS2 (<b>B</b>), JNK1 (<b>C</b>), JNK2 (<b>D</b>), MAP4K4 (<b>E</b>), ABL1 (<b>F</b>) in primary epidermal keratinocytes (3 repetitions) with preserved (dark grey) and silenced (tilted) expression of YAP under the influence of increasing doses of UVB. Data presented as fold change (columns) with geometric standard deviations (bars). Asterisks above columns indicate level of statistical significance (ns—not significant, * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.001) in comparison to controls.</p>
Full article ">Figure 4
<p>mRNA expression of studied Hippo pathway regulators: LATS1 (<b>A</b>), LATS2 (<b>B</b>), JNK1 (<b>C</b>), JNK2 (<b>D</b>), MAP4K4 (<b>E</b>), ABL1 (<b>F</b>) in primary epidermal keratinocytes (2 repetitions) with preserved (dark grey) and silenced (tilted) expression of YAP under the influence of increasing doses of narrowband UVB. Data presented as fold change (columns) with geometric standard deviations (bars). Asterisks above columns indicate level of statistical significance (ns—not significant, * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.001) in comparison to controls.</p>
Full article ">
19 pages, 3588 KiB  
Article
A Proprietary Punica granatum pericarp Extract, Its Antioxidant Properties Using Multi-Radical Assays and Protection Against UVA-Induced Damages in a Reconstructed Human Skin Model
by Steve Thomas Pannakal, Steven Durand, Julie Gizard, Peggy Sextius, Emilie Planel, Emilie Warrick, Damien Lelievre, Celine Lelievre, Joan Eilstein, Floriane Beaumard, Arpita Prasad, Sanketh Shetty, Arun Duraisamy, Kumar Gaurav, Sherluck John, Adrien Benazzouz, Xavier Fastinger, Dhimoy Roy and Vishal Sharma
Antioxidants 2025, 14(3), 301; https://doi.org/10.3390/antiox14030301 - 28 Feb 2025
Viewed by 247
Abstract
Background: Within the solar ultraviolet (UV) spectrum, ultraviolet A rays (UVA, 320–400 nm), although less energetic than ultraviolet B rays (UVB, 280–320 nm), constitute at least 95% of solar UV radiation that penetrates deep into the skin The UV rays are associated with [...] Read more.
Background: Within the solar ultraviolet (UV) spectrum, ultraviolet A rays (UVA, 320–400 nm), although less energetic than ultraviolet B rays (UVB, 280–320 nm), constitute at least 95% of solar UV radiation that penetrates deep into the skin The UV rays are associated with both epidermal and dermal damage resulting from the generation of reactive oxygen species (ROS). Among them, the longest UVA wavelengths (UVA1, 340–400 nm) can represent up to 75% of the total UV energy. Therefore, UVA radiation is linked to various acute and chronic conditions, including increased skin pigmentation and photoaging. Despite many advances in the skin photoprotection category, there is still a growing demand for natural daily photoprotection active ingredients that offer broad protection against skin damage caused by UVA exposure. In our quest to discover new, disruptive, next generation of photoprotective ingredients, we were drawn to pomegranate, based on its diverse polyphenolic profile. We investigated the pericarp of the fruit, so far considered as byproducts of the pomegranate supply chain, to design a novel patented extract “POMAOX” with a desired spectrum of phenolic components comprising of αβ-punicalagins, αβ-punicalins and ellagic acid. Methods: Antioxidant properties of POMAOX were measured using in-tubo standard tests capable of revealing a battery of radical oxygen species (ROS): peroxyl radical (ORAC), singlet oxygen (SOAC), superoxide anion (SORAC), peroxynitrite (NORAC), and hydroxyl radical (HORAC). In vitro, confirmation of antioxidant properties was first performed by evaluating protection against UVA-induced lipid peroxidation in human dermal fibroblasts (HDF), via the release of 8 iso-prostanes. The protection offered by POMAOX was further validated in a 3D in vitro reconstructed T-SkinTM model, by analyzing tissue viability/morphology and measuring the release of Matrix Metallopeptidase 1 (MMP-1) & pro-inflammatory mediators (IL-1α, IL-1ra, IL-6, IL-8, GM-CSF, and TNF-α) after UVA1 exposure. Results: POMAOX displayed strong antioxidant activity against peroxynitrite (NORAC) at 1.0–3.0 ppm, comparable to the reference vitaminC, as well as singlet oxygen (SOAC) at 220 ppm, and superoxide radicals with a SORAC value of 500 ppm. Additionally, POMAOX demonstrated strong photoprotection benefit at 0.001% concentration, offering up to 74% protection against UVA-induced lipid peroxidation on HDF, in a similar range as the positive reference, Vitamin E at 0.002% (50 µM), and with higher efficacy than ellagic acid alone at 5 µM. Moreover, our pomegranate-derived extract delivered photoprotection at 0.001%, mitigating dermal damages induced by UVA1, through inhibition of MMP-1 and significant inhibition of pro-inflammatory mediators release (including IL-1α, IL-1ra, IL-6, IL-8, GM-CSF, and TNFα) on an in vitro reconstructed full-thickness human skin model with a similar level of protection to that of Vitamin C tested at 0.035% (200 µM). Conclusions: Overall, the novel pomegranate-derived extract “POMAOX” significantly reduced the impact of UVA on human skin, due to its broad-spectrum antioxidant profile. These findings suggest that POMAOX could offer enhanced protection against the detrimental effects of UV exposure, addressing the growing consumer demand for strong photoprotection with skincare benefits. Full article
(This article belongs to the Section Natural and Synthetic Antioxidants)
Show Figures

Figure 1

Figure 1
<p>Green Extraction Technology of POMAOX.</p>
Full article ">Figure 2
<p>Evaluation of the photoprotective potential of POMAOX on lipid peroxidation under UVA exposure in human dermal fibroblasts (HDFs). (<b>a</b>) Evaluation of POMAOX cytotoxicity in UVA- or sham-exposed (No UVA) HDFs, (<b>b</b>) UVA-induced lipid peroxidation in HDFs pre-treated for 24 h with POMAOX or pure ellagic acid. Vitamin E (alpha-tocopherol) at 50 µM was used as a positive reference. The release of 8-isoProstanes (8isoP) in the cell supernatants was assayed 2 h 30 after UVA exposure. Lipid peroxidation is expressed as a percentage of 8isoP release by treated, UVA-exposed cells compared to untreated, UVA-exposed cells (UVA control, 100%). The release of 8isoP in untreated, sham-exposed cells (No UV control) is used as a baseline. Bar graphs represent mean ± SD of 3 independent experiments. ** Significant difference compared to the UV-exposed control (<span class="html-italic">p</span> &lt; 0.01, Mann Whitney statistical test).</p>
Full article ">Figure 3
<p>Evaluation of the photoprotective potential of POMAOX against UVA1-induced damage on reconstructed T-Skin<sup>TM</sup> model. All the UVA1 exposures were done at 35 J/cm<sup>2</sup>. Vitamin C at 200 µM was used as a positive reference. MMP-1 and cytokines release were normalized for each condition by corresponding fibroblasts number. (<b>a</b>) Tissue morphology (HES histology) in sham-exposed (No UVA1), untreated UVA1-exposed, vehicle exposed, VitC 200 µM exposed, POMAOX 0.0001% and 0.001% exposed tissues (<b>b</b>) Dermal fibroblasts counting on tissues pre-treated for 24 h with POMAOX, then UVA1 exposed and post-treated for 48 h. Fibroblast number is expressed as a percentage of fibroblast number in POMAOX or Vitamin C treated and exposed compared to exposed vehicle control respectively DMSO 0.1% and culture medium (untreated). Scatter plot represents mean ± SD of 3 independent experiments. (<b>c</b>) The release of MMP-1 in the supernatants was assayed 48 h after UVA1 exposure. MMP-1 release is expressed as a percentage of MMP-1 release in POMAOX or Vitamin C treated and exposed compared to exposed vehicle control respectively DMSO 0.1% and culture medium (untreated). Scatter plot represents mean ± SD of 3 independent experiments. (<b>d</b>) IL-8 quantification in the supernatants was assayed 48 h after UVA1 exposure. Il-8 level is expressed as a percentage of IL-8 level in POMAOX or Vitamin C treated and exposed compared to exposed vehicle control respectively DMSO 0.1% and culture medium (untreated). Scatter plot represents mean ± SD of 3 independent experiments.</p>
Full article ">Figure 3 Cont.
<p>Evaluation of the photoprotective potential of POMAOX against UVA1-induced damage on reconstructed T-Skin<sup>TM</sup> model. All the UVA1 exposures were done at 35 J/cm<sup>2</sup>. Vitamin C at 200 µM was used as a positive reference. MMP-1 and cytokines release were normalized for each condition by corresponding fibroblasts number. (<b>a</b>) Tissue morphology (HES histology) in sham-exposed (No UVA1), untreated UVA1-exposed, vehicle exposed, VitC 200 µM exposed, POMAOX 0.0001% and 0.001% exposed tissues (<b>b</b>) Dermal fibroblasts counting on tissues pre-treated for 24 h with POMAOX, then UVA1 exposed and post-treated for 48 h. Fibroblast number is expressed as a percentage of fibroblast number in POMAOX or Vitamin C treated and exposed compared to exposed vehicle control respectively DMSO 0.1% and culture medium (untreated). Scatter plot represents mean ± SD of 3 independent experiments. (<b>c</b>) The release of MMP-1 in the supernatants was assayed 48 h after UVA1 exposure. MMP-1 release is expressed as a percentage of MMP-1 release in POMAOX or Vitamin C treated and exposed compared to exposed vehicle control respectively DMSO 0.1% and culture medium (untreated). Scatter plot represents mean ± SD of 3 independent experiments. (<b>d</b>) IL-8 quantification in the supernatants was assayed 48 h after UVA1 exposure. Il-8 level is expressed as a percentage of IL-8 level in POMAOX or Vitamin C treated and exposed compared to exposed vehicle control respectively DMSO 0.1% and culture medium (untreated). Scatter plot represents mean ± SD of 3 independent experiments.</p>
Full article ">Figure 3 Cont.
<p>Evaluation of the photoprotective potential of POMAOX against UVA1-induced damage on reconstructed T-Skin<sup>TM</sup> model. All the UVA1 exposures were done at 35 J/cm<sup>2</sup>. Vitamin C at 200 µM was used as a positive reference. MMP-1 and cytokines release were normalized for each condition by corresponding fibroblasts number. (<b>a</b>) Tissue morphology (HES histology) in sham-exposed (No UVA1), untreated UVA1-exposed, vehicle exposed, VitC 200 µM exposed, POMAOX 0.0001% and 0.001% exposed tissues (<b>b</b>) Dermal fibroblasts counting on tissues pre-treated for 24 h with POMAOX, then UVA1 exposed and post-treated for 48 h. Fibroblast number is expressed as a percentage of fibroblast number in POMAOX or Vitamin C treated and exposed compared to exposed vehicle control respectively DMSO 0.1% and culture medium (untreated). Scatter plot represents mean ± SD of 3 independent experiments. (<b>c</b>) The release of MMP-1 in the supernatants was assayed 48 h after UVA1 exposure. MMP-1 release is expressed as a percentage of MMP-1 release in POMAOX or Vitamin C treated and exposed compared to exposed vehicle control respectively DMSO 0.1% and culture medium (untreated). Scatter plot represents mean ± SD of 3 independent experiments. (<b>d</b>) IL-8 quantification in the supernatants was assayed 48 h after UVA1 exposure. Il-8 level is expressed as a percentage of IL-8 level in POMAOX or Vitamin C treated and exposed compared to exposed vehicle control respectively DMSO 0.1% and culture medium (untreated). Scatter plot represents mean ± SD of 3 independent experiments.</p>
Full article ">
Back to TopTop